Name | Ranimustine |
---|---|
Synonyms |
Cymerin
MCNU MFCD00866369 Thymerin RCL L16,919-6 1-(2-chloroethyl)-1-nitroso-3-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxy-oxan-2-yl]methyl]urea Ranomustine |
Description | Ranimustine (MCNU) is a nitrosourea alkylating agent, can be used for research of chronic myelogenous leukemia and polycythemia vera[1][3][4]. |
---|---|
Related Catalog | |
In Vivo | Ranimustine reduces spermidine and spermine in the corpus striatum, and spermine in the diencephalon, but increases putrescine in the corpus striatum and combined thalamus and hypothalamus[2]. |
Density | 1.69 g/cm3 |
---|---|
Molecular Formula | C10H18ClN3O7 |
Molecular Weight | 327.71900 |
Exact Mass | 327.08300 |
PSA | 140.92000 |
Index of Refraction | 1.616 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
Hazard Codes | T |
---|---|
Risk Phrases | R25:Toxic if swallowed. R41:Risk of serious damage to eyes. R43:May cause sensitization by skin contact. |
Safety Phrases | S26-S36/37/39-S45 |
RIDADR | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | XU7700000 |
Packaging Group | III |
Hazard Class | 6.1 |
~42% 58994-96-0 |
Literature: Sosnovsky; Rao Journal of Pharmaceutical Sciences, 1991 , vol. 80, # 7 p. 693 - 699 |
~% 58994-96-0 |
Literature: Sosnovsky; Rao Journal of Pharmaceutical Sciences, 1991 , vol. 80, # 7 p. 693 - 699 |
Precursor 2 | |
---|---|
DownStream 0 |